Evaluation of opioid modulation in major depressive disorder
about
Neurobiology of opioid dependence in creating addiction vulnerabilitySex Differences in Kappa Opioid Receptor Function and Their Potential Impact on AddictionNeurobiology of hedonic tone: the relationship between treatment-resistant depression, attention-deficit hyperactivity disorder, and substance abuseKappa Opioid Receptor-Induced Aversion Requires p38 MAPK Activation in VTA Dopamine NeuronsComparison of abuse, suspected suicidal intent, and fatalities related to the 7-day buprenorphine transdermal patch versus other opioid analgesics in the National Poison Data System.Constitutive activation of kappa opioid receptors at ventral tegmental area inhibitory synapses following acute stress.The Link between Depression and Chronic Pain: Neural Mechanisms in the Brain.New targets for rapid antidepressant action.Antidepressant-like Effects of Buprenorphine are Mediated by Kappa Opioid Receptors.A role for the mu opioid receptor in the antidepressant effects of buprenorphine.Investigational drugs in recent clinical trials for treatment-resistant depression.The Behavioral Effects of the Antidepressant Tianeptine Require the Mu-Opioid Receptor.Beyond serotonin: newer antidepressants in the future.Association Between Placebo-Activated Neural Systems and Antidepressant Responses: Neurochemistry of Placebo Effects in Major Depression.Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder.Opioid system and human emotions.Chronic Kappa opioid receptor activation modulates NR2B: Implication in treatment resistant depressionKappa opioid receptor antagonism and chronic antidepressant treatment have beneficial activities on social interactions and grooming deficits during heroin abstinence.Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in miceKappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.Effects of buprenorphine on responses to emotional stimuli in individuals with a range of mood symptomatology.Reversal of stress-induced social interaction deficits by buprenorphine.Antidepressant-like effects of BU10119, a novel buprenorphine analogue with mixed κ/μ receptor antagonist properties, in mice.The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic ReviewNa⁺, K⁺-ATPase Signaling and Bipolar Disorder
P2860
Q26742048-1B8E281F-E8CD-4579-AAD0-8EB73393EF19Q26770785-300C412B-467F-4B19-BB75-E69FDF6A549BQ28076105-64618974-AB16-4FE8-9513-9418167BD96CQ28267475-0AD84AF0-85FA-459F-A862-1670022B3A00Q31147169-5ED9004F-29C3-468F-B7E0-6DD98C39159DQ33558914-D70C45B4-0658-48A6-A147-49EDAC8684B5Q33863747-B5A85F87-ED24-4CFD-9FAA-D1ACF5528059Q34507177-3695A167-1F0E-4FCD-83A5-44B0AB0A71EFQ34518271-801E7935-3972-4090-905D-37D81AF1E1F5Q34544184-266A47CB-BAA2-4C63-AFFD-4D4A7872EE95Q34549390-8918D8E8-345B-48AD-9796-086890094BD7Q34553463-C5631B59-F413-4FBA-B161-854A506C4099Q34557706-0641BC43-91C8-4D29-A76E-7495D0E56BBFQ36593892-69A4A172-5B76-43EF-A75C-1BD2C1BD16C1Q38543238-63AE99B5-E13F-4DB5-8E3F-4D6E9755A95EQ39231627-06382F47-ECAB-45D9-B346-F1F44ED97E89Q41107282-0756E6C6-7966-4C82-920F-CDF0CD8F7509Q41505543-86B29B2B-FD7E-4C41-9542-C892691FDE5CQ41537125-2C0565F4-D831-4F51-ABDD-3EDA0BE89452Q41639865-CB1458EC-362C-47FF-9F9E-A1A03B9D3668Q47657602-071E6F08-7E07-42FE-A2C9-5F67F494BBB3Q47659749-6C40126A-7B71-4DA3-A5A4-6232055EA44DQ47753097-639C7774-BFBE-44F8-BF1F-16EB14621B37Q58776450-DB1F817E-4789-44C0-AB1D-F40BC74BCD31Q58796804-053E7B0E-B41E-4831-B044-75C46875B5C5
P2860
Evaluation of opioid modulation in major depressive disorder
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Evaluation of opioid modulation in major depressive disorder
@ast
Evaluation of opioid modulation in major depressive disorder
@en
Evaluation of opioid modulation in major depressive disorder
@nl
type
label
Evaluation of opioid modulation in major depressive disorder
@ast
Evaluation of opioid modulation in major depressive disorder
@en
Evaluation of opioid modulation in major depressive disorder
@nl
prefLabel
Evaluation of opioid modulation in major depressive disorder
@ast
Evaluation of opioid modulation in major depressive disorder
@en
Evaluation of opioid modulation in major depressive disorder
@nl
P2093
P2860
P356
P1476
Evaluation of opioid modulation in major depressive disorder
@en
P2093
Elliot Ehrich
Emilio Fernandez
Maurizio Fava
Reese Jones
Richard Leigh-Pemberton
Ryan Turncliff
Yangchun Du
P2860
P2888
P304
P356
10.1038/NPP.2014.330
P407
P577
2014-12-18T00:00:00Z
P5875
P6179
1050156623